Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.

Employees

Sector

Pharmaceuticals

More about the company

Real-time Euronext Paris			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

10-05	Stallergenes Greer Ltd Announces Appointment of Anette Erika Weber as Director, Effective September 24, 2026	CI
09-28	Stallergenes Greer Ltd Announces Termination of Andreas Christian Amrein as Director, Effective September 15, 2026	CI

Market Cap	724M 813M 664M 603M 1.13B 76.79B 1.16B 7.94B 3.18B 40.64B 3.05B 2.98B 129B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	724M 812M 664M 603M 1.13B 76.77B 1.16B 7.93B 3.18B 40.63B 3.05B 2.98B 129B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

10-05	Stallergenes Greer Ltd Announces Appointment of Anette Erika Weber as Director, Effective September 24, 2026	CI
09-28	Stallergenes Greer Ltd Announces Termination of Andreas Christian Amrein as Director, Effective September 15, 2026	CI
07-16	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-04	Stallergenes Greer Ltd Announces Termination of Nicola Lamacchia as Director on April 30, 2026	CI
05-04	Stallergenes Greer Ltd Appoints Andreas Christian Amrein as Director on April 30, 2026	CI
25-10-06	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-07	Stallergenes Greer Ltd Announces Termination of Nunzio Michele Antonelli as Director	CI
25-01-09	European Commission Approves the Extension of the Indication of Palforzia to the Treatment of Toddlers with Confirmed Peanut Allergy	CI
24-09-30	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-07-11	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
23-05-25	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI
22-05-05	Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-01-17	Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	CI

18-01-25	Stallergenes Greer : comments on share price movement	PU
17-10-04	Stallergenes Greer : 04/10/2017 - Director/PDMR Shareholding. Released October 4, 2017	PU
17-10-03	Stallergenes Greer : 03/10/2017 - Director/PDMR Shareholding	PU
17-06-19	Stallergenes Greer : First real-world evidence shows long term benefits of sublingual immunotherapy to control allergic rhinitis and potentially prevent allergic asthma	PU
17-05-03	Stallergenes Greer : NOTIFICATION TO SHAREHOLDERS OF ANNUAL GENERAL MEETING ON 8 JUNE 2017	PU

Stallergenes Greer Stock

Stocks

STAGR

GB00BZ21RF93

Pharmaceuticals

Valuation: Stallergenes Greer

Latest news: Stallergenes Greer

Press Releases: Stallergenes Greer

News in other languages: Stallergenes Greer

Managers and Directors: Stallergenes Greer

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

23-11-06	AB Science : Le secteur pharmaceutique signe un accord de branche sur la transition écologique
19-05-17	Stallergenes Greer : radiation du titre ce jour
19-05-17	Stallergenes Greer : fin de partie à la Bourse de Paris
19-05-14	EN DIRECT DES MARCHES : EDF, Vinci, Ipsen, Europlasma, Erytech, Bayer, Volkswagen...
19-05-14	Trump, la carotte après le bâton

Manager	Title	Age	Since
Andreas Amrein CEO	Chief Executive Officer	-	2025-03-31
Amer Jaber COO	Chief Operating Officer	-	2018-12-31
Daniel Smith CTO	Chief Tech/Sci/R&D Officer	-	2016-04-10

Director	Title	Age	Since
Francesco Pietro Crispino BRD	Director/Board Member	-	2019-05-06
Nicola Lamacchia BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STALLERGENES GREER	-.--%	+0.14%	-	-	0
ELI LILLY AND COMPANY	+1.01%	+10.97%	+57.65%	+140.20%	1,255B
JOHNSON & JOHNSON	+2.96%	+1.24%	+46.85%	+80.88%	641B
ABBVIE INC.	+1.83%	+1.77%	+34.81%	+106.13%	505B
ROCHE HOLDING AG	+1.25%	-0.73%	+49.96%	+66.94%	381B
MERCK & CO., INC.	+2.78%	+5.34%	+77.02%	+42.28%	357B
NOVARTIS AG	+2.10%	+3.90%	+32.30%	+59.38%	303B
ASTRAZENECA PLC	+1.92%	+9.87%	+11.94%	+36.47%	286B
AMGEN INC.	+3.94%	+5.86%	+61.21%	+75.31%	249B
GILEAD SCIENCES, INC.	+4.23%	+9.57%	+41.81%	+114.97%	208B
Average	+2.05%	+2.67%	+45.95%	+80.28%	418.52B
Weighted average by Cap.	+1.95%	+3.90%	+48.66%	+93.93%

	2023	2024 *
Net sales	-	-
Net income	-4.51M -5.06M -4.13M -3.76M -7.06M -478M -7.22M -49.39M -19.8M -253M -18.98M -18.57M -801M	-
Net Debt	24.35M 27.33M 22.33M 20.29M 38.15M 2.58B 39.02M 267M 107M 1.37B 103M 100M 4.33B	-